215 related articles for article (PubMed ID: 34418335)
1. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves' disease patients.
Listewnik MH; Piwowarska-Bilska H; Jasiakiewicz K; Birkenfeld B
Adv Clin Exp Med; 2021 Sep; 30(9):913-921. PubMed ID: 34418335
[TBL] [Abstract][Full Text] [Related]
2. The effect of radioiodine treatment on the characteristics of TRAb in Graves' disease.
Fang Y; Du WH; Zhang CX; Zhao SX; Song HD; Gao GQ; Dong M
BMC Endocr Disord; 2021 Nov; 21(1):238. PubMed ID: 34847904
[TBL] [Abstract][Full Text] [Related]
3. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
Sawicka N; Sowiński J
Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091
[TBL] [Abstract][Full Text] [Related]
4. DYNAMIC CHANGES OF TRAb AND TPOAb AFTER RADIOIODINE THERAPY IN GRAVES' DISEASE.
Dong Q; Liu X; Wang F; Xu Y; Liang C; Du W; Gao G
Acta Endocrinol (Buchar); 2017; 13(1):72-76. PubMed ID: 31149151
[TBL] [Abstract][Full Text] [Related]
5. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.
Nygaard B; Knudsen JH; Hegedüs L; Scient AV; Hansen JE
J Clin Endocrinol Metab; 1997 Sep; 82(9):2926-30. PubMed ID: 9284721
[TBL] [Abstract][Full Text] [Related]
6. Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies.
Rubio IG; Perone BH; Silva MN; Knobel M; Medeiros-Neto G
Thyroid; 2005 Feb; 15(2):134-9. PubMed ID: 15753672
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
8. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
9. TRAb elevations occurred even in the third trimester; a case of a mother of a child with neonatal thyroid dysfunction, who received radioactive iodine therapy for Graves' disease.
Suzuki N; Yoshihara A; Yoshimura Noh J; Kinoshita K; Ohnishi J; Saito M; Sugino K; Ito K
Endocr J; 2020 Oct; 67(10):1019-1022. PubMed ID: 32522908
[TBL] [Abstract][Full Text] [Related]
10. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
12. Age moderates the associations between TRAbs, free T3 and outcomes of Graves' disease patients with radioactive iodine treatment.
Lu L; Gao C; Zhang N
Clin Endocrinol (Oxf); 2021 Feb; 94(2):303-309. PubMed ID: 32734611
[TBL] [Abstract][Full Text] [Related]
13. Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study.
Zheng W; Jian T; Guizhi Z; Zhaowei M; Renfei W
Nucl Med Commun; 2012 Jan; 33(1):97-101. PubMed ID: 22008631
[TBL] [Abstract][Full Text] [Related]
14. Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease.
Alnaqdy A; Al-Maskari M
Med Princ Pract; 2005; 14(4):209-12. PubMed ID: 15961927
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.
Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y
Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Lu JY; Chen KH; Shih SR; Wen FY; Wu WC; Chen TC; Hu FC
Endocr Pract; 2023 Feb; 29(2):89-96. PubMed ID: 36396015
[TBL] [Abstract][Full Text] [Related]
17. Follow-Up of Thyroid Function in Children With Neonatal Hyperthyroidism.
Pyrżak B; Rumińska M; Witkowska-Sędek E; Kucharska A
Front Endocrinol (Lausanne); 2022; 13():877119. PubMed ID: 35600602
[TBL] [Abstract][Full Text] [Related]
18. High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves' Disease.
Tay WL; Chng CL; Tien CS; Loke KS; Lam WW; Fook-Chong SM; Tong AK
Ann Acad Med Singap; 2019 Jun; 48(6):181-187. PubMed ID: 31377762
[TBL] [Abstract][Full Text] [Related]
19. Thyroid volume is the key predictor of hyperthyroidism remission after radioactive iodine therapy in pediatric patients.
Sheremeta M; Korchagina M; Trukhin A; Nagaeva E; Bezlepkina O; Peterkova V
Eur J Pediatr; 2023 Nov; 182(11):4931-4937. PubMed ID: 37606704
[TBL] [Abstract][Full Text] [Related]
20. Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy.
Quah NQX; Sobti MM; Wren AM; Scawn R; Kalogianni E; Cleland J; Maenhout A
Nucl Med Commun; 2024 Feb; 45(2):103-107. PubMed ID: 37982569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
